Xenon Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Xenon Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 22.7% bzw. 66.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 26.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -44.2% betragen.
Wichtige Informationen
22.7%
Wachstumsrate der Gewinne
26.8%
EPS-Wachstumsrate
Biotechs Gewinnwachstum | 24.1% |
Wachstumsrate der Einnahmen | 66.5% |
Zukünftige Eigenkapitalrendite | -44.2% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 18 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?
Mar 16Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 61 | -306 | -267 | -277 | 12 |
12/31/2025 | 9 | -269 | -231 | -249 | 16 |
12/31/2024 | 2 | -225 | -218 | -239 | 16 |
3/31/2024 | N/A | -189 | -158 | -154 | N/A |
12/31/2023 | N/A | -182 | -151 | -145 | N/A |
9/30/2023 | N/A | -175 | -150 | -143 | N/A |
6/30/2023 | 0 | -164 | -137 | -131 | N/A |
3/31/2023 | 1 | -148 | -119 | -114 | N/A |
12/31/2022 | 9 | -126 | -101 | -98 | N/A |
9/30/2022 | 13 | -113 | -88 | -86 | N/A |
6/30/2022 | 21 | -91 | -73 | -71 | N/A |
3/31/2022 | 23 | -83 | -69 | -67 | N/A |
12/31/2021 | 18 | -81 | -72 | -70 | N/A |
9/30/2021 | 20 | -66 | -64 | -62 | N/A |
6/30/2021 | 18 | -59 | -61 | -58 | N/A |
3/31/2021 | 29 | -37 | -58 | -56 | N/A |
12/31/2020 | 32 | -29 | -51 | -48 | N/A |
9/30/2020 | 30 | -28 | -18 | -15 | N/A |
6/30/2020 | 27 | -28 | -13 | -11 | N/A |
3/31/2020 | 14 | -38 | -11 | -9 | N/A |
12/31/2019 | 7 | -42 | -6 | -5 | N/A |
9/30/2019 | 4 | -39 | -33 | -32 | N/A |
6/30/2019 | N/A | -44 | -39 | -38 | N/A |
3/31/2019 | N/A | -42 | -36 | -35 | N/A |
12/31/2018 | N/A | -34 | -35 | -35 | N/A |
9/30/2018 | 0 | -34 | -35 | -34 | N/A |
6/30/2018 | 0 | -27 | -30 | -29 | N/A |
3/31/2018 | 0 | -27 | -31 | -30 | N/A |
12/31/2017 | 0 | -31 | N/A | -29 | N/A |
9/30/2017 | 1 | -29 | N/A | -27 | N/A |
6/30/2017 | 1 | -29 | N/A | -22 | N/A |
3/31/2017 | 1 | -27 | N/A | -21 | N/A |
12/31/2016 | 2 | -23 | N/A | -20 | N/A |
9/30/2016 | 5 | -21 | N/A | -20 | N/A |
6/30/2016 | 9 | -17 | N/A | -21 | N/A |
3/31/2016 | 12 | -10 | N/A | -17 | N/A |
12/31/2015 | 16 | -16 | N/A | -18 | N/A |
9/30/2015 | 17 | -2 | N/A | -16 | N/A |
6/30/2015 | 26 | 5 | N/A | -5 | N/A |
3/31/2015 | 27 | 4 | N/A | -4 | N/A |
12/31/2014 | 28 | 13 | N/A | 0 | N/A |
9/30/2014 | 29 | 6 | N/A | 1 | N/A |
6/30/2014 | 27 | 4 | N/A | -1 | N/A |
3/31/2014 | 27 | 4 | N/A | -1 | N/A |
12/31/2013 | 27 | 4 | N/A | -3 | N/A |
9/30/2013 | 25 | 0 | N/A | 19 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: XENE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: XENE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: XENE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: XENEDie Einnahmen des Unternehmens (66.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).
Hohe Wachstumseinnahmen: XENEDie Einnahmen des Unternehmens (66.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: XENE wird voraussichtlich in 3 Jahren unrentabel sein.